497 related articles for article (PubMed ID: 34038804)
1. Epigenetic regulation in Huntington's disease.
Hyeon JW; Kim AH; Yano H
Neurochem Int; 2021 Sep; 148():105074. PubMed ID: 34038804
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics of Huntington's Disease.
Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M
Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552
[TBL] [Abstract][Full Text] [Related]
3. Nucleolar dysfunction in Huntington's disease.
Lee J; Hwang YJ; Ryu H; Kowall NW; Ryu H
Biochim Biophys Acta; 2014 Jun; 1842(6):785-90. PubMed ID: 24184605
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic mechanisms of neurodegeneration in Huntington's disease.
Lee J; Hwang YJ; Kim KY; Kowall NW; Ryu H
Neurotherapeutics; 2013 Oct; 10(4):664-76. PubMed ID: 24006238
[TBL] [Abstract][Full Text] [Related]
5. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
6. The role of Twist1 in mutant huntingtin-induced transcriptional alterations and neurotoxicity.
Pan Y; Zhu Y; Yang W; Tycksen E; Liu S; Palucki J; Zhu L; Sasaki Y; Sharma MK; Kim AH; Zhang B; Yano H
J Biol Chem; 2018 Jul; 293(30):11850-11866. PubMed ID: 29891550
[TBL] [Abstract][Full Text] [Related]
7. Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease.
Kim C; Yousefian-Jazi A; Choi SH; Chang I; Lee J; Ryu H
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830381
[TBL] [Abstract][Full Text] [Related]
8. DNA Methylation in Huntington's Disease.
Zsindely N; Siági F; Bodai L
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884540
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation in Huntington's disease: Implications for transgenerational effects.
Thomas EA
Neurosci Lett; 2016 Jun; 625():34-9. PubMed ID: 26522374
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis.
Glajch KE; Sadri-Vakili G
J Huntingtons Dis; 2015; 4(1):1-15. PubMed ID: 25813218
[TBL] [Abstract][Full Text] [Related]
11. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
Podvin S; Reardon HT; Yin K; Mosier C; Hook V
J Neurol; 2019 Mar; 266(3):551-564. PubMed ID: 29956026
[TBL] [Abstract][Full Text] [Related]
12. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of DNA Methyltransferases Blocks Mutant Huntingtin-Induced Neurotoxicity.
Pan Y; Daito T; Sasaki Y; Chung YH; Xing X; Pondugula S; Swamidass SJ; Wang T; Kim AH; Yano H
Sci Rep; 2016 Aug; 6():31022. PubMed ID: 27516062
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic alterations mediate iPSC-induced normalization of DNA repair gene expression and TNR stability in Huntington's disease cells.
Mollica PA; Zamponi M; Reid JA; Sharma DK; White AE; Ogle RC; Bruno RD; Sachs PC
J Cell Sci; 2018 Jul; 131(13):. PubMed ID: 29898922
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
16. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
17. Neuroinflammation and the role of epigenetic-based therapies for Huntington's disease management: the new paradigm.
Temgire P; Arthur R; Kumar P
Inflammopharmacology; 2024 Jun; 32(3):1791-1804. PubMed ID: 38653938
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
Wang F; Fischhaber PL; Guo C; Tang TS
Epigenomics; 2014 Jun; 6(3):287-97. PubMed ID: 25111483
[TBL] [Abstract][Full Text] [Related]
19. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
20. Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.
Mehler MF; Petronglo JR; Arteaga-Bracho EE; Gulinello ME; Winchester ML; Pichamoorthy N; Young SK; DeJesus CD; Ishtiaq H; Gokhan S; Molero AE
J Neurosci; 2019 Mar; 39(10):1892-1909. PubMed ID: 30626701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
